On October 1, 2020 Sumgen Biotech of Hangzhou reported that it completed a $32 million Series B funding round to advance its portfolio of novel immunotherapy antibodies (Press release, Hangzhou Shangjian Biotechnology, OCT 1, 2020, View Source [SID1234567967]). The round was led by Addor Capital and co-led by Cowin Capital and Sinowisdom Investment. The proceeds will be used to fund clinical trials of the company’s pipeline of ten oncology mAbs and construction of an antibody production facility in Hangzhou. Also participating in the round were BOCOM International, Shanghai Haoshuo Investment and Dynamic Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!